The Solid Tumor Fusion Gene Panel is designed for identification of somatic known and novel gene fusions (or rarely pathogenic alternative transcripts due to gene rearrangements) in cancer patients. The test involves 145 clinical genes, which include kinases, transcriptional factors and others found to be recurrently altered in a variety of solid tumors. This panel evaluates 907 regions of interest within 145 clinical genes for the potential rearrangements.
14 days from receipt of required specimen in performing lab
Methodology
The Solid Tumor Fusion Panel uses Archer's AMP™ technology to interrogate specific regions of genes. This assay features a highly optimized oligonucleotide probe pool with specificity for the recurrent break points in the fusion partner genes that are recurrently rearranged in a variety of solid tumors. This panel evaluates 907 regions of interest within 145 clinical genes for the potential rearrangements. Sequencing of fusion libraries is performed on Illumina Miseq.
Use
The Solid Tumor Fusion Panel evaluates the gene fusion in cancer patients. The test involves 145 clinical genes, which include kinases, transcriptional factors and others found to be recurrently altered in a variety of solid tumors. The findings of this assay act in conjunction with clinical history and pathologic diagnoses for the clinical management of patients with different solid tumor malignancies.
Limitations
The panel should not be used for detecting residual fusions. This test cannot detect gene fusions outside the regions of interest (ROI) defined by the test. This assay is at risk of false negatives when tumor purity is low and/or RNA quality is suboptimal. Some fusions may not be detected due to local sequence characteristics or the presence of pseudogene.
Specimen Type
10 unstained formalin-fixed paraffin-embedded (FFPE) slides with ≥20% of neoplastic cells on the entire slide or in the circled tumor area. An H&E from the same tumor block is required.
Shipping and Handling Instructions
Transport specimen at room temperature.
Causes for Rejection
Incorrect tissue type, damaged slides, tissue quantity not sufficient
Test Information
Test Name
Solid Tumor Fusion Gene Panel
Test Number
LAB9064
CPT Codes
81456
Test Includes
The Solid Tumor Fusion Gene Panel is designed for identification of somatic known and novel gene fusions (or rarely pathogenic alternative transcripts due to gene rearrangements) in cancer patients. The test involves 145 clinical genes, which include kinases, transcriptional factors and others found to be recurrently altered in a variety of solid tumors. This panel evaluates 907 regions of interest within 145 clinical genes for the potential rearrangements.
14 days from receipt of required specimen in performing lab
Methodology
The Solid Tumor Fusion Panel uses Archer's AMP™ technology to interrogate specific regions of genes. This assay features a highly optimized oligonucleotide probe pool with specificity for the recurrent break points in the fusion partner genes that are recurrently rearranged in a variety of solid tumors. This panel evaluates 907 regions of interest within 145 clinical genes for the potential rearrangements. Sequencing of fusion libraries is performed on Illumina Miseq.
Use
The Solid Tumor Fusion Panel evaluates the gene fusion in cancer patients. The test involves 145 clinical genes, which include kinases, transcriptional factors and others found to be recurrently altered in a variety of solid tumors. The findings of this assay act in conjunction with clinical history and pathologic diagnoses for the clinical management of patients with different solid tumor malignancies.
Limitations
The panel should not be used for detecting residual fusions. This test cannot detect gene fusions outside the regions of interest (ROI) defined by the test. This assay is at risk of false negatives when tumor purity is low and/or RNA quality is suboptimal. Some fusions may not be detected due to local sequence characteristics or the presence of pseudogene.
Specimen Collection and Handling
Specimen Type
10 unstained formalin-fixed paraffin-embedded (FFPE) slides with ≥20% of neoplastic cells on the entire slide or in the circled tumor area. An H&E from the same tumor block is required.
Shipping and Handling Instructions
Transport specimen at room temperature.
Causes for Rejection
Incorrect tissue type, damaged slides, tissue quantity not sufficient
